ArticleFrontiers in oncology2025
Analysis of the molecular subtypes and prognostic models of anoikis-related genes in colorectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a malignant tumor originating from the epithelial cells of colon or rectum. Currently, the main treatment strategy is surgery with chemotherapy and radiotherapy, but the 5-year survival rate is only 63%. Therefore, new therapeutic targets should be discovered and identified to improve survival. This study explored the critical role of anoikis-related genes in CRC development, investigated the regulatory mechanism and identified potential therapeutic drugs using data from the TCGA database, offering a theoretical foundation for CRC diagnosis and treatment. Methods: Anoikis-related genes differentially expressed in CRC tissues compared to normal tissues were identified using data from the TCGA dataset. Prognostic gene signatures were constructed using both univariate and multivariate Cox regression models. Validation of target gene expression was performed by Western blotting and qRT-PCR. To elucidate the regularity mechanisms underlying the identified gene signature, KEGG, GO, immune infiltration analysis and ssGSEA were conducted. Additionally, various computational algorithms were employed to evaluate the immunotherapeutic responses of different risk groups. The oncoPredict package predicted candidate chemotherapy agents. Results: Based on screening and identification results, we established three anoikis-related genes: LEP, HAMP, and FAM43B, as the prognostic prediction genes of CRC. We successfully constructed the study model and demonstrated that the risk score of the anoikis-related prognostic prediction signature is an independent prognostic factor in overall survival. Additionally, the results of immune microenvironment infiltration showed that the high-risk score group had a greater infiltration of the M0, M1, and M2 macrophages. In the immunotherapy cohort, the prognosis of patients with a high score, as judged by the study model, was significantly better. The risk score of the anoikis-related prognostic prediction gene is associated with the immunotherapy response in metastatic colorectal cancer. Conclusions: Our study reports on the identification of anoikis-related gene subtypes and the construction of a prognostic signature in CRC, which, in turn, can provide a basis for further study of the molecular mechanism, clinical diagnosis, and treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.